NCT05885048 Impact of Gonadotoxic Therapies on Fertility
| NCT ID | NCT05885048 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Michael von Wolff |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,000 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2028-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: * in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); * in males, if cancer therapies reduce sperm concentration (sperm quality).
Eligibility Criteria
Inclusion Criteria: * Patients with cancer or with benign reasons undergoing chemotherapy and/or radiotherapy of the pelvis (females) and the testicles (males) and/or immune therapy; * Willing to participate; * Austria: 14-50 years old (adolescents and adults), Germany: 18-50 years old, Switzerland: 14-50 years old (adolescents and adults); * Serum hormone analysis before gonadotoxic therapy (females) or serum hormone analysis and sperm analysis before gonadotoxic therapy (males). Exclusion Criteria: * Missing consent; * Language barrier.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.